Ibrutinib dose intensity in high‐risk chronic lymphocytic leukemiaGabriela Forestieri, Adalgisa Condoluci, Silvia Rasi et al.|Hematological Oncology|2022Cited by 2
IBRUTINIB TOLERABILITY AND OUTCOME IN PATIENTS WITH HIGH‐RISK CHRONIC LYMPHOCYTIC LEUKEMIAAdalgisa Condoluci, Davide Rossi, Lodovico Terzi-di-Bergamo et al.|Hematological Oncology|2021Cited by 0
Author response for "Ibrutinib dose intensity in high‐risk chronic lymphocytic leukemia"Gabriela Forestieri, Adalgisa Condoluci, Lodovico Terzi di Bergamo et al.|Unknown|2022Cited by 0